Find clinical trials for Triple Negative Breast Cancer in Budapest, Budapest
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Triple Negative Breast Cancer trials near Budapest, Budapest, HUN:
PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer
mg twice per day. Capivasertib or placebo could be interrupted for up to 4 weeks for toxicity.Tumor assessments included computed tomograph...
Phase 2
Budapest, Hungary and 45 other locations
for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple...
Phase 2
Tatabánya, Hungary and 74 other locations
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...
Phase 3
Budapest, Hungary and 228 other locations
previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...
Phase 3
Budapest, Hungary and 516 other locations
after induction with first-line chemotherapy plus pembrolizumab in triple negative breast cancer (TNBC). The prim...
Phase 2
Budapest, Hungary and 121 other locations
with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors...
Phase 3
Budapest, Hungary and 505 other locations
with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who car...
Phase 3
Budapest, Hungary and 76 other locations
III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple...
Phase 3
Budapest, Hungary and 260 other locations
with standard of care treatment (docetaxel) or another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of ...
Phase 1, Phase 2
Törökbálint, Hungary and 56 other locations
The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.
Phase 1, Phase 2
Budapest, Hungary and 114 other locations
Clinical trials
Research sites
Resources
Legal